MNPR
Monopar Therapeutics·NASDAQ
--
--(--)
--
--(--)
MNPR fundamentals
During Q4 2025, Monopar Therapeutics (MNPR) reported revenue of --, a YoY change of 0.00%. Net income was -5.20M, a YoY change of 52.40%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q2,2018 | Q3,2018 | Q4,2018 | Q1,2019 | Q2,2019 | Q3,2019 | Q4,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Apr 1, 2018 | Jul 1, 2018 | Oct 1, 2018 | Jan 1, 2019 | Apr 1, 2019 | Jul 1, 2019 | Oct 1, 2019 | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Jun 30, 2018 | Sep 30, 2018 | Dec 31, 2018 | Mar 31, 2019 | Jun 30, 2019 | Sep 30, 2019 | Dec 31, 2019 | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 840.00K -- | 667.53K -- | 926.36K -- | 1.41M -- | 932.11K +10.97% | 759.45K +13.77% | 1.22M +32.23% | 1.14M -19.28% | 1.46M +57.08% | 1.65M +117.00% | 2.26M +84.57% | 1.89M +66.79% | 2.09M +42.91% | 2.46M +49.21% | 2.68M +18.59% | 2.46M +29.69% | 2.76M +32.07% | 2.41M -2.10% | 2.91M +8.50% | 2.53M +2.76% | 2.33M -15.75% | 2.07M -14.18% | 1.91M -34.27% | 1.72M -31.75% | 1.79M -23.17% | 1.57M -23.77% | 11.07M +479.22% | 3.22M +86.95% | 3.23M +80.81% | 4.09M +159.89% | 6.16M -44.42% | 16.70M -- |
Selling, General and Administrative Expenses | 347.35K -- | 363.85K -- | 405.38K -- | 571.71K -- | 602.82K +73.55% | 539.60K +48.30% | 641.12K +58.15% | 791.61K +38.46% | 631.63K +4.78% | 392.06K -27.34% | 628.38K -1.99% | 687.94K -13.10% | 615.97K -2.48% | 631.70K +61.12% | 698.44K +11.15% | 779.25K +13.27% | 684.88K +11.19% | 675.12K +6.87% | 806.03K +15.40% | 871.67K +11.86% | 733.50K +7.10% | 749.47K +11.01% | 876.40K +8.73% | 757.28K -13.12% | 657.81K -10.32% | 590.62K -21.19% | 1.15M +31.22% | 1.58M +108.44% | 1.50M +128.68% | 1.50M +154.53% | 2.21M +92.53% | 6.80M -- |
General and Administrative Expenses | -- -- | -- -- | 1.56M -- | -- -- | -- -- | -- -- | 2.36M +51.30% | -- -- | -- -- | -- -- | 2.44M +3.75% | -- -- | -- -- | -- -- | 2.63M +7.79% | -- -- | -- -- | -- -- | 2.95M +11.82% | -- -- | -- -- | 749.47K -- | 876.40K -70.24% | 757.28K -- | 657.81K -- | 590.62K -21.19% | 1.15M +31.22% | 1.58M +108.44% | 1.50M +128.68% | 1.50M +154.53% | 2.21M +92.53% | 6.80M -- |
Research and Development Expenses | 492.65K -- | 303.68K -- | 520.98K -- | 835.60K -- | 329.29K -33.16% | 219.85K -27.61% | 583.78K +12.05% | 344.41K -58.78% | 832.50K +152.81% | 1.26M +471.27% | 1.63M +179.62% | 1.21M +250.39% | 1.48M +77.35% | 1.83M +45.50% | 1.98M +21.46% | 1.68M +39.04% | 2.08M +40.78% | 1.73M -5.20% | 2.10M +6.07% | 1.65M -1.46% | 1.59M -23.27% | 1.32M -24.00% | 1.04M -50.76% | 966.11K -41.57% | 1.13M -29.08% | 984.28K -25.24% | 9.92M +858.35% | 1.64M +70.10% | 1.73M +52.96% | 2.59M +163.11% | 3.94M -60.29% | 9.90M -- |
Operating Income | -840.00K -- | -667.53K -- | -926.36K -- | -1.41M -- | -932.11K -10.97% | -759.45K -13.77% | -1.22M -32.23% | -1.14M +19.28% | -1.46M -57.08% | -1.65M -117.00% | -2.26M -84.57% | -1.89M -66.79% | -2.09M -42.91% | -2.46M -49.21% | -2.68M -18.59% | -2.46M -29.69% | -2.76M -32.07% | -2.41M +2.10% | -2.91M -8.50% | -2.53M -2.76% | -2.33M +15.75% | -2.07M +14.18% | -1.91M +34.27% | -1.72M +31.75% | -1.79M +23.17% | -1.57M +23.77% | -11.07M -479.22% | -3.22M -86.95% | -3.23M -80.81% | -4.09M -159.89% | -6.16M +44.42% | -16.70M -- |
Non-Operating Income (Loss) | 19.06K -- | 27.35K -- | 35.90K -- | 31.07K -- | 26.41K +38.57% | 23.37K -14.55% | 18.04K -49.76% | 45.14K +45.26% | 18.32K -30.62% | 8.54K -63.45% | 132.30K +633.54% | 10.70K -76.30% | 12.23K -33.27% | 577 -93.24% | 525 -99.60% | 464 -95.66% | 417 -96.59% | 7.70K +1234.14% | 12.66K +2311.43% | 90.49K +19401.72% | 128.22K +30647.72% | 112.26K +1358.30% | 98.07K +674.67% | 82.17K -9.20% | 73.47K -42.70% | 270.63K +141.07% | 149.04K +51.96% | 596.85K +626.40% | 780.77K +962.63% | 655.47K +142.21% | 954.43K +540.41% | 2.99M -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 122.40K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 171.28K -- | 0 -- | -- -- | -- -- | 0 -100.00% | 0 -- | -- -- |
Net Interest Expense | -19.06K -- | -27.35K -- | -35.90K -- | -31.07K -- | -26.41K -38.57% | -23.37K +14.55% | -18.04K +49.76% | -45.14K -45.26% | -18.32K +30.62% | -8.54K +63.45% | -9.90K +45.10% | -10.70K +76.30% | -12.23K +33.27% | -577 +93.24% | -525 +94.70% | -464 +95.66% | -417 +96.59% | -7.70K -1234.14% | -12.66K -2311.43% | -90.49K -19401.72% | -128.22K -30647.72% | -112.26K -1358.30% | -98.07K -674.67% | -82.17K +9.20% | -73.47K +42.70% | -99.34K +11.51% | -149.04K -51.96% | -596.85K -626.40% | -780.77K -962.63% | -655.47K -559.80% | -954.43K -540.41% | -2.99M -- |
Interest Income | 19.06K -- | 27.35K -- | 35.90K -- | 31.07K -- | 26.41K +38.57% | 23.37K -14.55% | 18.04K -49.76% | 45.14K +45.26% | 18.32K -30.62% | 8.54K -63.45% | 9.90K -45.10% | 10.70K -76.30% | 12.23K -33.27% | 577 -93.24% | 525 -94.70% | 464 -95.66% | 417 -96.59% | 7.70K +1234.14% | 12.66K +2311.43% | 90.49K +19401.72% | 128.22K +30647.72% | 112.26K +1358.30% | 98.07K +674.67% | 82.17K -9.20% | 73.47K -42.70% | 99.34K -11.51% | 149.04K +51.96% | 596.85K +626.40% | 780.77K +962.63% | 655.47K +559.80% | 954.43K +540.41% | 2.99M -- |
Pretax Income From Continuing Operations | -820.94K -- | -640.18K -- | -890.46K -- | -1.38M -- | -905.70K -10.32% | -736.08K -14.98% | -1.21M -35.53% | -1.09M +20.73% | -1.45M -59.63% | -1.64M -122.73% | -2.13M -76.36% | -1.88M -72.71% | -2.08M -43.88% | -2.46M -49.96% | -2.68M -25.94% | -2.46M -30.40% | -2.76M -32.82% | -2.40M +2.39% | -2.90M -8.05% | -2.43M +0.90% | -2.20M +20.37% | -1.95M +18.58% | -1.81M +37.37% | -1.64M +32.59% | -1.72M +22.03% | -1.30M +33.24% | -10.93M -502.32% | -2.62M -59.94% | -2.45M -43.04% | -3.44M -163.56% | -5.20M +52.40% | -13.72M -- |
Income Tax Expense | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -820.94K -- | -640.18K -- | -890.46K -- | -1.38M -- | -905.70K -10.32% | -736.08K -14.98% | -1.21M -35.53% | -1.09M +20.73% | -1.45M -59.63% | -1.64M -122.73% | -2.13M -76.36% | -1.88M -72.71% | -2.08M -43.88% | -2.46M -49.96% | -2.68M -25.94% | -2.46M -30.40% | -2.76M -32.82% | -2.40M +2.39% | -2.90M -8.05% | -2.43M +0.90% | -2.20M +20.37% | -1.95M +18.58% | -1.81M +37.37% | -1.64M +32.59% | -1.72M +22.03% | -1.30M +33.24% | -10.93M -502.32% | -2.62M -59.94% | -2.45M -43.04% | -3.44M -163.56% | -5.20M +52.40% | -13.72M -- |
Net Income Attributable to Owners of the Company | -820.94K -- | -640.18K -- | -890.46K -- | -1.38M -- | -905.70K -10.32% | -736.08K -14.98% | -1.21M -35.53% | -1.09M +20.73% | -1.45M -59.63% | -1.64M -122.73% | -2.13M -76.36% | -1.88M -72.71% | -2.08M -43.88% | -2.46M -49.96% | -2.68M -25.94% | -2.46M -30.40% | -2.76M -32.82% | -2.40M +2.39% | -2.90M -8.05% | -2.43M +0.90% | -2.20M +20.37% | -1.95M +18.58% | -1.81M +37.37% | -1.64M +32.59% | -1.72M +22.03% | -1.30M +33.24% | -10.93M -502.32% | -2.62M -59.94% | -2.45M -43.04% | -3.44M -163.56% | -5.20M +52.40% | -13.72M -- |
Net Income Attributable to Common Stockholders | -820.94K -- | -640.18K -- | -890.46K -- | -1.38M -- | -905.70K -10.32% | -736.08K -14.98% | -1.21M -35.53% | -1.09M +20.73% | -1.45M -59.63% | -1.64M -122.73% | -2.13M -76.36% | -1.88M -72.71% | -2.08M -43.88% | -2.46M -49.96% | -2.68M -25.94% | -2.46M -30.40% | -2.76M -32.82% | -2.40M +2.39% | -2.90M -8.05% | -2.43M +0.90% | -2.20M +20.37% | -1.95M +18.58% | -1.81M +37.37% | -1.64M +32.59% | -1.72M +22.03% | -1.30M +33.24% | -10.93M -502.32% | -2.62M -59.94% | -2.45M -43.04% | -3.44M -163.56% | -5.20M +52.40% | -13.72M -- |
Other Comprehensive Income | -1.58K -- | -806 -- | -11 -- | -2.13K -- | 1.07K +167.57% | -8.74K -984.24% | 1.23K +11236.36% | -4.04K -89.99% | 3.46K +223.99% | 1.51K +117.28% | 2.17K +77.22% | 2.77K +168.65% | -55 -101.59% | 9 -99.40% | 1.99K -8.48% | -584 -121.05% | 21.21K +38663.64% | 25.52K +283444.44% | -34.04K -1813.29% | 22.84K +4011.82% | -24.57K -215.82% | -3.27K -112.83% | -18.08K +46.89% | 18.36K -19.62% | 4.03K +116.39% | -19.25K -488.11% | 46.98K +359.85% | 1.58K -91.37% | 99.36K +2367.37% | -65.88K -242.25% | 119.69K +154.75% | 154.76K -- |
Total Comprehensive Income | -822.52K -- | -640.99K -- | -890.47K -- | -1.38M -- | -904.63K -9.98% | -744.82K -16.20% | -1.21M -35.39% | -1.09M +20.56% | -1.44M -59.44% | -1.64M -119.91% | -2.13M -76.36% | -1.88M -71.82% | -2.08M -44.22% | -2.46M -50.09% | -2.68M -25.98% | -2.46M -30.62% | -2.74M -31.80% | -2.37M +3.43% | -2.93M -9.40% | -2.41M +1.86% | -2.22M +18.86% | -1.96M +17.57% | -1.83M +37.48% | -1.62M +32.71% | -1.71M +23.07% | -1.32M +32.37% | -10.88M -493.81% | -2.62M -61.65% | -2.35M -37.57% | -3.50M -164.71% | -5.08M +53.29% | -13.56M -- |
Total Comprehensive Income Attributable to Owners of the Company | -822.52K -- | -640.99K -- | -890.47K -- | -1.38M -- | -904.63K -9.98% | -744.82K -16.20% | -1.21M -35.39% | -1.09M +20.56% | -1.44M -59.44% | -1.64M -119.91% | -2.13M -76.36% | -1.88M -71.82% | -2.08M -44.22% | -2.46M -50.09% | -2.68M -25.98% | -2.46M -30.62% | -2.74M -31.80% | -2.37M +3.43% | -2.93M -9.40% | -2.41M +1.86% | -2.22M +18.86% | -1.96M +17.57% | -1.83M +37.48% | -1.62M +32.71% | -1.71M +23.07% | -1.32M +32.37% | -10.88M -493.81% | -2.62M -61.65% | -2.35M -37.57% | -3.50M -164.71% | -5.08M +53.29% | -13.56M -- |
Basic EPS | -0.09 -- | -0.07 -- | -- -- | -0.15 -- | -0.1 -11.11% | -0.08 -14.29% | -0.11 -- | -0.1 +33.33% | -0.14 -40.00% | -0.15 -87.50% | -0.19 -72.73% | -0.16 -60.00% | -0.17 -21.43% | -0.2 -33.33% | -0.21 -10.53% | -0.19 -18.75% | -0.22 -29.41% | -0.19 +5.00% | -0.22 -4.76% | -0.19 -- | -0.16 +27.27% | -0.69 -263.16% | -0.12 +45.45% | -0.51 -168.42% | -0.49 -206.25% | -0.37 +46.38% | -1.79 -1391.67% | -0.38 +25.49% | -0.35 +28.57% | -0.48 -29.73% | -0.78 +56.42% | -1.99 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.69 -- | -- -- | -0.51 -- | -0.49 -- | -0.37 +46.38% | -- -- | -0.38 +25.49% | -0.35 +28.57% | -0.48 -29.73% | -- -- | -- -- |
Diluted EPS | -0.09 -- | -0.07 -- | -- -- | -0.15 -- | -0.1 -11.11% | -0.08 -14.29% | -- -- | -0.1 +33.33% | -0.14 -40.00% | -0.15 -87.50% | -- -- | -0.16 -60.00% | -0.17 -21.43% | -0.2 -33.33% | -- -- | -0.19 -18.75% | -0.22 -29.41% | -0.19 +5.00% | -- -- | -0.19 -- | -0.16 +27.27% | -0.69 -263.16% | -- -- | -0.51 -168.42% | -0.49 -206.25% | -0.37 +46.38% | -- -- | -0.38 +25.49% | -0.35 +28.57% | -0.48 -29.73% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.69 -- | -- -- | -0.51 -- | -0.49 -- | -0.37 +46.38% | -- -- | -0.38 +25.49% | -0.35 +28.57% | -0.48 -29.73% | -- -- | -- -- |
You can ask Aime
What were the key takeaways from Monopar Therapeutics’s earnings call?What factors drove the changes in Monopar Therapeutics's revenue and profit?What is the market's earnings forecast for Monopar Therapeutics next quarter?What does Monopar Therapeutics do and what are its main business segments?What is the revenue and EPS growth rate for Monopar Therapeutics year over year?Did Monopar Therapeutics beat or miss consensus estimates last quarter?What is Monopar Therapeutics's latest dividend and current dividend yield?What guidance did Monopar Therapeutics's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
